Organisation paid for research Program year 2025 Source: CMS Open Payments

The Ohio State University

Neither a doctor nor a teaching hospital

Research payments

$119,300,809

11,712 payments

Through program year 2025, The Ohio State University is reported as receiving $119,300,809 in research payments, across 11,712 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $22,947,397 2,511
2024 Research $20,374,584 1,879
2023 Research $20,354,154 1,455
2022 Research $18,389,769 1,376
2021 Research $14,939,494 1,439
2020 Research $13,895,595 1,613
2019 Research $8,399,816 1,439

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $15,929,468 255 payments
  2. AbbVie, Inc. $11,214,011 363 payments
  3. Regeneron Pharmaceuticals, Inc. $10,038,788 880 payments
  4. Amgen Inc. $7,475,459 39 payments
  5. Pfizer Inc. $6,182,034 489 payments
  6. Acerta Pharma LLC $3,891,745 18 payments
  7. Janssen Research & Development, LLC $3,577,386 558 payments
  8. Merck Sharp & Dohme Corporation $3,479,207 281 payments
  9. AstraZeneca Pharmaceuticals LP $3,390,575 23 payments
  10. GlaxoSmithKline, LLC. $3,306,867 219 payments
Studies the money was for Research payments · program years 2019–2025
  1. Phase 2 study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL $6,213,672 16 payments
  2. Phase 1/2 Fih Study of Regn5458 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) in Patients With Relapsed Or Refractory Multiple Myeloma $3,690,505 79 payments
  3. A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer $3,592,717 4 payments
  4. A PHASE 1/2 STUDY OF REGN4018 (A MUC16xCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER $3,475,137 89 payments
  5. A Phase Ib Study of ACP196 in combination with Obinutuzumab for Patients with Untreated CLL or SLL or PLL $3,111,508 3 payments
  6. Prospective Randomized Phase 2 study of Acalabrutinib and Obinutuzumab or Venetoclax in previously untreated or minimally treated CLL $3,023,208 3 payments
  7. A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300) $2,671,979 1 payment
  8. A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (NHL) $2,355,057 7 payments
  9. A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (Loxo-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin Cll-322) $2,140,809 5 payments
  10. 0000000000000000000000000000000000000000000000000000000000000000217423 $2,102,381 27 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $632,503 76 payments
  2. Other $371,210 141 payments
  3. Non-patient care $153,325 9 payments
  4. Professional salary support $38,615 2 payments
  5. Overhead $18,402 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record